METI will hold GGX x TCFD Summit
27.9.2023 15:35:00 EEST | Business Wire | Press release
From 10:00 on October 2 (Mon.), the Ministry of Economy, Trade and Industry (METI) will hold the Global Green Transformation (GGX) Conference and the TCFD Summit, which until now have attracted participation from a wide range of sectors including global industry, finance, governments, regulators, and international organizations, will be held jointly. In order to further develop discussions on transition finance, avoided emissions, industry decarbonization, and other topics related to how business and finance contribute to decarbonization, the event will promote mutual cooperation between the government, business, and financial sectors, and hold discussions to lead the international rule-making process to achieve both emission reductions and economic growth.
- Outline of Global Green Transformation (GGX) Conference and the TCFD Summit
Date: October 2nd, 2023 10:00-17:00 (JST)
Organizer: Ministry of Economy, Trade and Industry (METI)
Co-organizer: TCFD Consortium, The World Business Council for Sustainable Development (WBCSD)
Format: Hybrid (On-Site and On-Line)
Web Site: https://tcfd-summit.go.jp/indexEn.html
- Online Registration
Online Registration Site: https://jcs.eventsair.com/ggxtcfd2023/attendeereg/Site/Register
*Registration deadline: Oct 1st (Sun.) (JST, GMT+9:00)
- Program
-
Opening Remarks
HATAKEYAMA Yojiro (Director-General, Industrial Science, Technology and Environment Policy Bureau, Ministry of Economy, Trade and Industry)
TOKURA Masakazu (Chairman, Keidanren (Japan Business Federation))
KATO Masahiko (Chairperson, Japanese Bankers Association)
David Atkin (CEO, Principles for Responsible Investment (PRI))
-
Keynote Speech 1
Gianluigi Benedetti (Ambassador, Embassy of Italy in Tokyo)
-
Panel Discussion 1 “Towards Net-Zero Society ~Industrial Decarbonisation~”
What efforts are needed towards creating a "Green Market" to accelerate industrial decarbonization, focusing on the creation of demand?
[Moderator]
Peter Bakker (President and CEO, World Business Council for Sustainable Development (WBCSD))
[Panelist]
Nancy Gillis (Program Head, First Movers Coalition, World Economic Forum)
Rana Ghoneim (Chief, Energy Systems and Industrial Decarbonization Unit, United Nations Industrial Development Organization)
TEZUKA Hiroyuki (Fellow, Executive, JFE Steel Corporation)
MITA Noriyuki (Vice President, Sustainability Department, Mitsubishi Chemical Group Corporation *After October 1st)
KOBAYASHI Izuru (Deputy Director-General for Environmental Affairs, Ministry of Economy, Trade and Industry)
-
Panel Discussion 2 “Solution Provider and Avoided Emissions”
Companies are increasingly expected to provide solutions to social challenges. What is the potential of the idea of "avoided emissions" to evaluate a company's contribution to decarbonization of the society as a whole by providing solutions?
[Moderator]
HAYASHI Reiko (Director and Deputy President, BofA Securities Japan Co., Ltd.)
[Panelist]
Jason Mortimer (Head of Sustainable Investment - Fixed Income, Investment Department - Global Solutions, Nomura Asset Management)
UEHARA Hirotoshi (Executive Officer, Quality & Environment, CS, Panasonic Operational Excellence Co., Ltd.)
HIRUTA Takako (Country Leader, CS&Q, Schneider Electric Japan, Inc)
-
Keynote Speech 3
Emmanuel Faber (Chair, ISSB)
MIYAZONO Masataka (President, Government Pension Investment Fund)
MIZUNO Hiromichi (Founder And CEO, Good Steward Partners, LLC)
-
Panel Discussion 3 “Future of Climate-Related Financial Disclosures”
As climate-related financial disclosures rapidly expand, what efforts are needed going forward? How can disclosure promote transition finance?
[Moderator]
NAGAMURA Masaaki (Fellow, International Initiatives, Tokio Marine Holdings, Inc.)
[Panelist]
Alex Michie (Head of Secretariat, GFANZ)
IKEDA Satoshi (Chief Sustainable Finance Officer, Strategy Development And Management Bureau, Financial Services Agency)
ISHIKAWA Tomohiro (Chief Regulatory Engagement Officer, Corporate Planning Division, Mitsubishi UFJ Financial Group (MUFG))
KITAGAWA Keiko (General Manager, Sustainability Promotion Unit, Global Investor Relations Group, Finance Strategy and Planning Division, JERA Co., Inc.)
-
Keynote Speech 4
Mary Schapiro (Head, The TCFD Secretariat)
ITO Kunio (Chair, The TCFD Consortium)
-
Panel Discussion 4 “Further Promotion of Transition Finance”
As the understanding of the importance of transition finance grows globally, what efforts are needed to further promote investments toward decarbonization of corporates and the private financing towards them?
[Moderator]
KIHARA Shinichi (Director General for International Policy on Carbon Neutrality, Ministry of Economy, Trade and Industry)
[Panelist]
Nicholas Pfaff (Deputy Chief Executive, Head of Sustainable Finance, International Capital Market Association)
Sean Kidney (CEO, Climate Bonds Initiative)
Eila Kreivi (Director, Chief Sustainable Finance Advisor, Secretariat General, European Investment Bank)
KUBOTA Nobuhiko (Managing Executive Officer, General Manager of Technology & Intelligence Integration, IHI Corporation)
-
Closing Remarks
Peter Bakker (President and CEO, World Business Council for Sustainable Development (WBCSD))
*The above programs and speakers may be subject to change at the discretion of the organizer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230927620291/en/
Contact information
Contact information for inquiries
GGX x TCFD Summit 2023 Registration Desk
E-mail: ggxtcfd2023-reg@convention.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
